Phase II Multicenter, Double-blinded Clinical Trial of SP160412 in the Temporary Relief of Mild to Moderate (i.e,First Degree) Sunburn
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs SP 160412 (Primary) ; Chlorphenamine; Ibuprofen
- Indications Sunburn
- Focus Therapeutic Use
- Sponsors Sephoris Pharmaceuticals
- 20 Apr 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 Planned End Date changed from 1 Sep 2019 to 1 Nov 2019.
- 01 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Jan 2019.